IndraLab

Statements

Geldanamycin inhibits RIPK1. 5 / 5
| 1 4
eidos
"Compared with etanercept , a TNF-alpha inhibitor , geldanamycin inhibits the RIPK1 and NF-KB activity while augmenting the activation of caspase-8 to promote MH7A cell apoptosis , and inhibit TNF-alpha-induced necroptosis ."
35003139
reach
"Geldanamycin (GA), an antitumor of benzoquinone ansamycin (Stebbins et al., 1997), is an HSP-90 inhibitor and induces RIP degradation, followed by inhibition of NF-kappaB-mediated protection (Lewis et[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
12493534
reach
"Geldanamycin disrupted RIPK1 in MH7A, thereby inhibiting TNFalpha induced proinflammatory cytokine production and enhancing apoptosis."
33415454
reach
"Compared with etanercept, a TNF-α inhibitor, geldanamycin inhibits the RIPK1 and NF-KB activity while augmenting the activation of caspase-8 to promote MH7A cell apoptosis, and inhibit TNF-α-induced necroptosis."
35003139
reach
"Key Points * Geldanamycin (GM) disrupts RIPK1 and selectively inhibits the TNFR1 triggered NF-kappaB activation signaling pathway while enhancing the apoptosis signaling pathway upon TNFalpha stimulation, thereby redressing the balance between these two opposing signals in a human rheumatoid synovial cell line, MH7A."
33415454